^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR expression

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    19h
    PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. (PubMed, J Hematol Oncol)
    PACIFIC-5 met its primary endpoint of improved PFS after either cCRT or sCRT. Follow-up for overall survival is ongoing.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR expression
    |
    Imfinzi (durvalumab)
    2d
    Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis. (PubMed, Lung Cancer)
    PD-L1 ≥50 % was associated with over twofold risk of progression or death in EGFR-mutant NSCLC on first-line osimertinib. Supported by meta-analysis, results suggest PD-L1 expression is a negative prognostic factor, and these patients may benefit from intensified first-line strategies with prospective evaluation.
    Retrospective data • Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR expression
    |
    Tagrisso (osimertinib)
    4d
    Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death. (PubMed, Mol Ther Oncol)
    Furthermore, co-culturing immature dendritic cells with dying cancer cells targeted by EGFR and TF NIR-PIT agents mediated enhanced dendritic cell maturation, as indicated by increased expression of CD80, CD86, CD40, and HLADR. Taken together, our results suggested that all five investigated NIR-PIT agents have great potential to be applicable for ovarian cancer treatment.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha ) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CD40 (CD40 Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    EGFR expression
    4d
    Prognostic model for lung adenocarcinoma based on experimental drug-resistant cell lines and clinical patients. (PubMed, Front Mol Biosci)
    erlotinib-, gefitinib-, and osimertinib-resistant HCC827 cell lines were established by exposing them to increasing EGFR-TKIs concentrations. A nomogram (C-index = 0.7) integrated RiskScore with clinical factors for personalized prognosis. This model bridges in vitro resistance mechanisms with clinical immune landscapes, offering a tool to stratify patients for EGFR-TKIs, immunotherapies, or combinatorial strategies.
    Preclinical • Journal • IO biomarker
    |
    LYPD3 (LY6/PLAUR Domain Containing 3)
    |
    EGFR mutation • EGFR expression
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib
    8d
    Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis. (PubMed, Front Pharmacol)
    The objective response rate (ORR) was significantly increased by Kanglaite injection (RR = 1.52, 95% confidence interval [CI]: 1.07-2.15, p = 0.02)...Due to limitations in the assessed research, high-quality clinical studies with rigorous designs are required to confirm the findings. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024561845, Identifier CRD42024561845.
    Retrospective data • Review • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR expression
    |
    Kanglaite Injection (KLTi)
    8d
    Expression of the Epidermal Growth Factor Receptor (EGFR) Ligand Heparin-Binding EGF-Like Growth Factor (HB-EGF) in Sinonasal Inverted Papilloma. (PubMed, Cureus)
    Conclusion HB-EGF expression is a characteristic feature of SIP. ADAM12 and HIF-1α may contribute to the distinctive upregulation of HB-EGF observed in SIP.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ADAM12 (ADAM Metallopeptidase Domain 12)
    |
    EGFR expression
    8d
    Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models. (PubMed, J Biomed Opt)
    Cetuximab-IRDye800CW provides stable, tumor-specific, high-contrast fluorescence imaging in EGFR-high CRC models. These findings validate its molecular targeting capability and support its translational potential for fluorescence-guided CRC surgery.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    8d
    ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC. (PubMed, Invest New Drugs)
    To assess clinical relevance, blood samples from 109 gefitinib/erlotinib- and 54 osimertinib-treated patients were analyzed for these SNPs. These findings suggest that ABC transporter SNPs could be valuable biomarkers for personalized medicine in NSCLC. These findings suggest that ABC transporter SNPs may serve as valuable biomarkers for predicting EGFR-TKI efficacy in NSCLC patients with EGFR mutations, which will contribute to personalized medicine.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC10 (ATP Binding Cassette Subfamily C Member 10) • ABCC11 (ATP Binding Cassette Subfamily C Member 11)
    |
    EGFR mutation • EGFR expression
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib
    9d
    Network Pharmacology and Molecular Docking Reveal Neuroprotective Potential of Ligusticum wallichii in Alzheimer's Disease Therapy. (PubMed, Neuropsychiatr Dis Treat)
    In vitro studies demonstrated that these compounds significantly downregulated the expression of STAT3, EGFR, and HSP90AA1 in Neuro 2A cells. In conclusion, the results indicate that Ligusticum wallichii significantly downregulated STAT3, EGFR, and HSP90AA1 expression in Neuro 2A cells, providing mechanistic evidence that targeting these proteins may ameliorate neurodegenerative processes in Alzheimer's disease and highlighting Ligusticum wallichii's promising therapeutic potential.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    EGFR expression
    10d
    Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. (PubMed, Sci Rep)
    Interactions of Eltrombopag with EGFR, FAS, p53, and TNFα proteins were detected through molecular docking simulations. These findings highlight the potential of Eltrombopag olamine as a repurposed, multi-targeted therapeutic candidate for the treatment of breast and liver cancer.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAPK1 (Mitogen-activated protein kinase 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
    |
    EGFR expression
    |
    Promacta (eltrombopag)
    11d
    USP25 deubiquitinates cytosolic METTL3 to impede glioma proliferation via an m6A-independent pathway. (PubMed, iScience)
    Moreover, USP25 enhances EGFR expression through cytosolic METTL3, driving glioma progression. Our findings highlight that METTL3 undergoes distinct post-translational modifications based on its subcellular localization, providing new insights into the spatial regulation of METTL3 in gliomas.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • METTL3 (Methyltransferase Like 3) • USP25 (Ubiquitin Specific Peptidase 25)
    |
    EGFR expression
    16d
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010